Monitor for any commentary from management during the conference regarding financing plans for lacutamab or IPH4502, especially given the going concern risk highlighted in the recent 20-F. Absent such updates, this event is unlikely to move the stock materially.
Price Chart
Executive Summary
Innate Pharma announced that its executive team will participate in one-on-one investor meetings at the Kempen Life Sciences Conference on April 15-16, 2026. This is a routine investor relations event with no new financial or clinical data disclosed. The filing is contextually significant due to the company's recent going concern warning in its 20-F, but this 6-K itself contains no material updates.
Key Facts
- Innate Pharma executives will attend the Kempen Life Sciences Conference on April 15-16, 2026 in Amsterdam.
- The purpose is one-on-one investor meetings, typical for capital markets engagement.
- No new clinical, financial, or operational updates were provided in the filing.
- This follows a recent 20-F filing (April 1, 2026) that raised going concern risks due to funding gaps.
Financial Impact
No direct financial impact from this filing.
Risk Factors
- Continued lack of financing clarity increases dilution or partnership risk.
- Failure to secure funding could lead to clinical trial delays or cuts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-023471 |
| Document: a6k-iphx260403.htm | 0001628280-26-023471 |
| Document: 0001628280-26-023471-index-headers.html | 0001628280-26-023471 |
| Document: 0001628280-26-023471-index.html | 0001628280-26-023471 |
| Document: 0001628280-26-023471.txt | 0001628280-26-023471 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 23w ago | 6-K | $2.25 $1.65 | ▼ −26.67% | ▼ −32.96% | $1.51 (−32.93%) |
May 13, 2026 23w ago | 6-K | $1.50 $1.65 | ▼ −10.00% | ▼ −5.56% | $1.51 (−0.60%) |
May 6, 2026 24w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +7.94% | $1.51 (+0.60%) |
Apr 23, 2026 26w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +4.98% | $1.51 (+0.60%) |
Apr 17, 2026 27w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +3.86% | $1.51 (+0.60%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 8, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +9.72% | $1.51 (+9.91%) |
Apr 3, 2026 29w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +6.71% | $1.51 (+9.91%) |
Apr 1, 2026 29w ago | 20-F | $1.37 $1.65 | ▼ −20.17% | ▼ −6.80% | $1.51 (−9.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers